Abstract

Cyclin-dependent kinase 2 (CDK2) is a crucial regulator of the eukaryotic cell cycle. However it is well established that monomeric CDK2 lacks regulatory activity, which needs to be aroused by its positive regulators, cyclins E and A, or be phosphorylated on the catalytic segment. Interestingly, these activation steps bring some dynamic changes on the 3D-structure of the kinase, especially the activation segment. Until now, in the monomeric CDK2 structure, three binding sites have been reported, including the adenosine triphosphate (ATP) binding site (Site I) and two non-competitive binding sites (Site II and III). In addition, when the kinase is subjected to the cyclin binding process, the resulting structural changes give rise to a variation of the ATP binding site, thus generating an allosteric binding site (Site IV). All the four sites are demonstrated as being targeted by corresponding inhibitors, as is illustrated by the allosteric binding one which is targeted by inhibitor ANS (fluorophore 8-anilino-1-naphthalene sulfonate). In the present work, the binding mechanisms and their fluctuations during the activation process attract our attention. Therefore, we carry out corresponding studies on the structural characterization of CDK2, which are expected to facilitate the understanding of the molecular mechanisms of kinase proteins. Besides, the binding mechanisms of CDK2 with its relevant inhibitors, as well as the changes of binding mechanisms following conformational variations of CDK2, are summarized and compared. The summary of the conformational characteristics and ligand binding mechanisms of CDK2 in the present work will improve our understanding of the molecular mechanisms regulating the bioactivities of CDK2.

Highlights

  • Cyclin-dependent kinases (CDKs), which belong to an important affiliated subfamily of Ser/Thr protein kinases, have been extensively studied due to their essential roles in cell division cycle, transcription, differentiation, neuronal functions, as well as apoptosis [1]

  • Being one member of the highly conserved protein kinases, Cyclin-dependent kinase 2 (CDK2) is a pivotal regulator of the eukaryotic cell cycle

  • Its monomer is inactive in the quiescent cells, which needs to be aroused by specific partners containing cyclins A and E, or be phosphorylated on the catalytic region

Read more

Summary

Introduction

Cyclin-dependent kinases (CDKs), which belong to an important affiliated subfamily of Ser/Thr protein kinases, have been extensively studied due to their essential roles in cell division cycle, transcription, differentiation, neuronal functions, as well as apoptosis [1]. A highly specific inhibitor of CDK2 (IC50 = 10 nM) [31], P276-00, exhibits potent anti-proliferative effects against several human tumor cells [32], and is undergoing phase I–II clinical trials [33]. The high sequence homology within the ATP binding sites of cellular kinases makes the work of designing small molecules like P276-00, which can effectively target CDK2 at its ATP binding site, more complex [27]. It is noteworthy that non-ATP competitive inhibitors, the other type of CDK2 inhibitors, which inhibit the substrates of CDK2−cyclin complexes and regulatory binding sites, have high specificity [23]. Several non-ATP competitive CDK2 inhibitors which show great potential for clinical applications have been developed, including Spa310 (a 39-residue peptide) and CIP (a p53-derived peptide) [34]. Analyzing the binding modes of these ligands as well as the structural characteristics of CDK2 can enhance our understanding of the molecular mechanisms regulating the activities of this protein kinase [36]

Characterization of Monomeric CDK2
Conformational Changes of CDK2 via Cyclin Binding
Conformational Changes of CDK2 via Phosphorylation
Changes of the Interaction via Conformational Fluctuations
Conclusions
Conflicts of Interest
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call